Ballet flats are a wardrobe staple loved for their effortless elegance and
versatility. From boardroom meetings to weekend brunches, they pair
beautifully with almost any outfit. Yet for all their charm, most ballet flats
come with a significant downside: virtually zero arch support. The flat, thin
soles that give them their sleek silhouette offer little in the way of structural
support for the foot, leaving the arch to work overtime with every step. For
the millions of people who wear them daily, this can lead to foot fatigue,
plantar fasciitis, and long-term musculoskeletal discomfort. The good news is
that with the right knowledge and a few smart solutions, you can enjoy the
look of ballet flats without sacrificing the health of your feet.

Why Arch Support Matters
The arch of the foot is a sophisticated engineering marvel. Composed of
bones, tendons, and ligaments, it acts as a natural shock absorber, distributing
body weight evenly and propelling movement forward. When the arch is
unsupported, it collapses slightly under load, a condition known as
overpronation. Over time, this places stress not only on the foot itself but also
on the ankles, knees, hips, and lower back. People who already have flat feet or
high arches are especially vulnerable, but even those with neutral arches can
develop problems after extended periods in unsupportive footwear.
Understanding this makes it clear that seeking arch support in ballet flats is not
vanity – it is a matter of long-term physical wellbeing.

Choosing Ballet Flats with Built-In Support
The simplest solution is to start at the source: choose ballet flats that are
engineered with support in mind. In recent years, several footwear brands have responded to consumer demand by creating flats that look traditional on
the outside but incorporate hidden structural elements on the inside. When
shopping, look for flats that feature a contoured footbed rather than a
completely flat insole. A slight curvature under the midfoot, even a few
millimetres, can make a significant difference over the course of a day. Brands
such as Vionic, Clarks, Ecco, and Naturalizer have developed collections
specifically designed to balance aesthetics with orthopedic functionality.
These shoes often include moulded insoles, firmer midsoles, and deeper heel
cups that cradle the foot and reduce pronation. While they may carry a
slightly higher price tag, the investment in your foot health is well worth it.

The Magic of Insoles and Orthotics
For those who already own a beloved pair of ballet flats – or simply prefer
a wider selection of styles – aftermarket insoles and custom orthotics offer a
practical and effective solution. The challenge with ballet flats is that they have
a very shallow profile, leaving little room for thick inserts. The key is to seek
out slim-profile arch support insoles specifically designed for flats and
low-profile shoes. Look for insoles made from materials such as memory
foam, EVA (ethylene vinyl acetate), or semi-rigid plastic that provide a firm
yet cushioned foundation. Products like Superfeet Black, Dr. Scholl’s For Her
flats insoles, and Pedag Viva Mini are popular options engineered to fit into
the tight confines of a ballet flat without bunching or slipping. When inserting
any insole, remove the existing sock liner from the shoe first to maximise
available space. For those with diagnosed foot conditions – such as plantar
fasciitis, flat feet, or bunions – custom orthotics prescribed by a podiatrist
represent the gold standard. These are moulded to the exact contour of your
foot and can be made thin enough to fit most ballet flats. While more
expensive upfront, custom orthotics address the specific biomechanical needs
of your foot in a way no over-the-counter product can replicate.

Selecting the Right Shoe Construction
Not all ballet flats are created equal, and construction quality plays a major
role in how supportive they can be. When examining a potential purchase,
perform a simple twist test: grip the toe and heel of the shoe and try to wring it
like a towel. A shoe that twists easily has little torsional rigidity and will do
little to support the arch. A good flat should resist twisting through the
midfoot while still allowing some flex at the toe box. The heel counter – the
stiff cup at the back of the shoe that wraps around the heel – is another critical
element. Press on it with your thumb. If it collapses easily, the shoe will not
hold your heel in proper alignment, which in turn affects the arch. Opt for
shoes with a firm, structured heel counter. Additionally, a slightly raised heel
of even 1 to 2 centimetres can reduce strain on the plantar fascia, which is why
some podiatrists recommend transitioning to ballet flats with the faintest of
kitten heels rather than a completely level sole.

Supplementary Strategies for Foot Health
Beyond the shoe itself, several complementary strategies can help protect
your arch while wearing flats. Stretching the plantar fascia and calf muscles
each morning – before you take your first steps – loosens the connective tissue
and reduces the shock placed on the arch throughout the day. A simple
exercise is to sit on the edge of the bed and pull your toes back gently toward
your shin, holding for 30 seconds on each side. Rotating your footwear is also
a wise habit. Wearing ballet flats every single day, without variation, amplifies
the cumulative stress on unsupported feet. Alternating between flats and more
supportive shoes – such as trainers or low-heeled boots with a proper insole –
gives the musculature of the foot time to recover. Foot-strengthening
exercises such as towel scrunches, marble pickups, and single-leg calf raises
also build the intrinsic muscles that help the arch support itself, reducing
reliance on external support over time.

Knowing When to Seek Professional Advice
If you experience persistent heel pain, a burning sensation along the sole,
or significant fatigue after short periods of walking, it is worth consulting a podiatrist or physiotherapist. These professionals can assess your gait,
measure your arch type, and recommend tailored solutions – from specific
insole brands and shoe models to targeted exercise programs. Pain is the
body’s signal that something is not right, and addressing it early can prevent
more serious conditions from developing.
Ballet flats need not be the enemy of foot health. With thoughtful shoe
selection, quality insoles, attention to construction, and a few supportive
habits, it is entirely possible to stride through the day in style and comfort.
Your feet carry you everywhere – they deserve a little extra care, even when
dressed in their most elegant shoes.

There is a particular kind of barefoot freedom that only a flip flop can
provide. The slap of foam against pavement, the instant ease of a shoe you can
kick off in a single motion, the breezy confidence of striding into summer
with your toes on display — these are sensory pleasures that millions of people
reach for every year. And yet, for decades, podiatrists and physiotherapists
watched that freedom with a certain professional unease. The traditional flip
flop, for all its charm, offered feet almost nothing in the way of structural
support. Flat, thin, and utterly indifferent to the complex biomechanics of the
human foot, the classic thong was footwear distilled to its absolute minimum.
Then, in 2011, an Australian physiotherapist decided enough was enough.

Origins: A Physio’s Passion Project
Archies Footwear was born out of a simple but compelling idea: what if a
flip flop could actually be good for your feet? The company’s founder, a
practising physical therapist in Australia, was frustrated watching patients
arrive in his clinic with sore heels, aching arches, and inflamed tendons —
only to discover they had been shuffling around all summer in flat,
unsupportive sandals. He set out to design a flip flop that retained everything
people loved about the style while incorporating the kind of orthotic support
typically found only in dedicated shoe insoles or clinical footwear. Working
with input from fellow physiotherapists and podiatrists, he developed a
prototype and began selling pairs from a stall at local markets. What started as
a passion project grew into one of the most talked-about footwear brands in
the world.

The Science Behind the Support
At the heart of Archies’ appeal is their signature arch support system,
which provides approximately 2.2 centimetres of orthotic-grade elevation
beneath the mid-foot. This might sound modest, but in the context of a flip
flop — a category of footwear that typically provides zero arch support — it
represents a genuine leap forward. The arch of the human foot is a
sophisticated load-bearing structure, a natural spring that absorbs shock,
distributes body weight, and propels us forward with each step. When that
arch collapses against a flat surface repeatedly over the course of a day, the
consequences ripple outward: plantar fasciitis, Achilles tendon strain, knee
discomfort, and even lower back pain can all trace their roots to inadequate
foot support. Archies address this by cradling the arch and encouraging the
foot to adopt a more neutral, biomechanically sound position.

Construction and Design
Beyond the arch support, Archies are engineered with several features that
set them apart from the average summer sandal. The footbed is made from a
specialised closed-cell foam that gradually moulds to the unique shape of the
wearer’s foot over the first few wears, creating a customised fit that improves
with time. The elevated heel promotes proper alignment, reducing strain on
the calf muscles and the Achilles tendon — a genuine benefit for anyone who
has ever ended a beach holiday limping from Achilles soreness. The strap is
designed to sit securely without gripping too tightly, accommodating a range
of foot widths while keeping the foot relaxed throughout the day. Perhaps
most practically, Archies use a one-piece moulded construction with no
separate plugs or components, eliminating the dreaded blowout that has
ended many a flip flop’s life mid-stride. The result is a sandal built to last
season after season.

A Rainbow of Choices
Archies have also recognised that foot health need not come at the cost of
personal expression. The range is available in an extensive palette of colours,
from core classics like black, navy, brown, and white to seasonal offerings in
coral, hot pink, mint, lemon, lilac, and acai purple. Crystal-finish variants add a touch of sparkle for those who like a little glamour with their orthotic
support. This breadth of choice has helped Archies appeal to a wide
demographic, from health-conscious older wearers managing chronic foot
pain to fashion-forward younger consumers who simply want a sandal that
looks great and feels even better. Celebrity endorsement has further amplified
the brand’s visibility; reports that actress Jennifer Aniston owns pairs in
multiple colours have done no harm at all to Archies’ cultural cachet.

The Clinical Perspective
The response from the podiatry and physiotherapy communities has been
broadly positive, if nuanced. Many practitioners now recommend Archies to
patients who insist on wearing flip flops during warmer months, viewing them
as a meaningful harm-reduction option compared to conventional flat
sandals. A podiatrist’s review published by City Step Podiatry in Chicago noted
that while Archies offer more arch support than virtually any standard flip
flop on the market, they are best suited to light, casual wear rather than
extended walking or days that demand a great deal of time on one’s feet. For
patients managing conditions such as plantar fasciitis, flat feet, or
overpronation, Archies can serve as a comfortable bridge between barefoot
informality and the structured support of a full shoe. They are not a
replacement for clinical orthotics or supportive closed-toe footwear in
demanding situations, but for the poolside, the beach, or a relaxed weekend
morning, they represent a category-defining improvement.

Customer Reception and Global Growth
The commercial success of Archies is a testament to how powerfully they
have resonated with everyday wearers. The brand has accumulated over
100,000 five-star reviews and is now stocked in thousands of retail outlets
across Australia, the United States, the United Kingdom, and beyond.
Customer testimonials repeatedly highlight the same experience: an initial
surprise at how firm the arch support feels, followed by a rapid break-in
period during which the foam softens and conforms to the foot, and then a
genuine reluctance to go back to anything else. Wearers report completing

tens of thousands of steps on city breaks and holidays in their Archies with a
comfort that conventional flip flops simply cannot match. The brand has also
cultivated a loyal following of repeat buyers, with many customers owning
multiple pairs in different colours — a sure sign that the product delivers on
its promises.

Giving Back
Archies Footwear has also distinguished itself through a commitment to
social responsibility. The company has donated more than 25,000 pairs of
sandals to Soles4Souls, a nonprofit organisation that redistributes footwear to
people in need around the world, combining sustainability with humanitarian
purpose. The brand has also supported Australian healthcare workers with
donated pairs — a gesture that aligns naturally with its physiotherapy origins
and its broader mission of promoting foot health and wellbeing. For
consumers increasingly mindful of the values behind the brands they support,
this dimension of the Archies story adds another layer of appeal.

A Revolution in Rubber
The story of Archies Arch Supporting Flip Flops is, at its core, a story about
not accepting the false choice between comfort and health. For generations,
summer footwear was something you simply endured — a trade-off between
the pleasure of easy, open shoes and the quiet punishment your feet paid for
it. Archies have demonstrated that this compromise was never actually
necessary. With thoughtful design, clinical input, and genuine attention to the
biomechanics of the human foot, it is entirely possible to build a flip flop that
feels wonderful, looks great, and actively supports the body that wears it.
Whether you are an athlete cooling down after training, a traveller exploring a
new city, or simply someone who wants to step out into a sunny day without
punishing your arches, Archies offer a compelling answer. The humble flip
flop has been reinvented — and your feet are all the better for it.

For a brief, glorious window in the late 2000s and early 2010s, a peculiar promise swept through the athletic footwear industry: you could get in shape simply by walking. No gym membership required. No gruelling workout regime. Just strap on the right pair of shoes, stroll to your car, and watch the calories evaporate. It was a marketer’s dream — and, as it turned out, a scientist’s nightmare. Nowhere was this story played out more vividly than in the short-lived chapter of Avia toning shoes.

A Brand with Pedigree

To understand the toning shoe era, it helps to know where Avia came from. Founded in 1979 in Oregon by Jerry Stubblefield — who, legend has it, coined the name mid-flight, inspired by the Latin word avis meaning “bird” — Avia quickly established itself as a genuine innovator in athletic footwear. The company’s cantilever sole design, which used a curved heel structure to absorb shock and provide stability, was widely imitated and became the technical foundation of the brand’s identity. By the late 1980s, Avia was a serious player: NBA stars like Scottie Pippen, Clyde Drexler, and John Stockton laced up their shoes, and in 1987, Reebok acquired the company for $180 million — a figure that underlined just how much the industry respected Avia’s engineering credentials.

After passing through several corporate hands — from Reebok to American Sporting Goods Corporation in the mid-1990s, and later to Sequential Brands Group — Avia retained its reputation as a workmanlike, technically credible brand. That reputation would make it a natural fit for the toning shoe trend, and also make its eventual stumble all the more damaging.

The Toning Shoe Gold Rush

The concept of the “toning shoe” was not born with Avia. Credit for that goes to MBT — Masai Barefoot Technology — a Swiss brand that launched in 1996, inspired by the idea that walking barefoot on uneven natural terrain, as the Masai people of East Africa were said to do, engaged more muscles and improved posture. MBT’s rocker-bottom sole mimicked this instability, and early adopters swore by the results. For years, MBT was a niche, physiotherapy-adjacent product sold for premium prices.

Then the mainstream brands smelled money. By 2009, Skechers had launched its Shape-Ups, Reebok introduced the EasyTone and RunTone, New Balance joined in, and Avia rolled out its own entry: the Avi-Motion and the iShape lines. The shoes all shared the same basic engineering logic — a curved, unstable, or cushioned sole designed to make each stride slightly unpredictable, theoretically forcing the wearer’s leg muscles, glutes, and core to work harder to compensate.

The marketing was breathless. Avia’s campaigns promised that wearing the Avi-Motion could help consumers “get in shape without setting foot in a gym.” Advertisements highlighted improvements in muscle tone, better posture, reduced back pain, and increased calorie burn — all from the simple act of wearing a particular shoe. Celebrity endorsements accompanied glossy infomercials. The toning shoe category ballooned into a multi-hundred-million-dollar segment seemingly overnight, driven largely by women seeking accessible, low-effort fitness solutions. Retailers could barely keep shelves stocked.

The Science Fights Back

The problem was that the claims were, to put it generously, not well supported by evidence. As sales soared, independent researchers began applying actual scientific rigour to the promises being made. The American Council on Exercise (ACE) commissioned a study that subjected toning shoes to controlled testing, measuring muscle activation and calorie expenditure in participants wearing toning shoes versus ordinary athletic sneakers.

The results were unambiguous and unflattering. The researchers found no statistically significant difference in muscle activation between toning shoes and regular footwear. There was no measurable increase in calorie burn. The instability that was supposed to be the mechanism of action — the secret engine driving all those promised fitness gains — simply did not translate into real physiological benefit in a controlled setting. The ACE concluded bluntly: “There is simply no evidence to support the claims that these shoes will help wearers exercise more intensely, burn more calories, or improve muscle strength and tone.”

More worrying still was an emerging body of evidence around injury risk. The same instability that was marketed as a benefit could, for some wearers, increase the risk of falls or ankle sprains. For people with pre-existing gait issues or reduced proprioception, the rocker sole was not a fitness tool — it was a hazard. Personal injury claims began to accumulate, and the legal system took notice.

Lawsuits and Regulatory Reckoning

The Federal Trade Commission, America’s consumer protection watchdog, moved decisively. In 2011, Reebok agreed to pay $25 million to settle FTC charges that its EasyTone and RunTone advertising was deceptive — that the brand had made health claims it could not substantiate. The following year, in 2012, Skechers agreed to an even larger settlement of $40 million, with the FTC finding that its Shape-Ups and related lines had been sold on the back of false and misleading advertising. The settlements required both companies to stop making unsubstantiated claims and to fund consumer refund programmes.

Avia did not escape scrutiny. A lawsuit — Laskowski v. Brown Shoe Co. — alleged that the Avia A9995WWSL toning shoe had been marketed with misrepresented health benefits while its design posed a significantly increased risk of falls. The plaintiff, Karen Laskowski, claimed she had sustained a fracture and developed a chronic pain condition as a result. While punitive damages and fraud claims were ultimately stripped from the case, the core negligence claims were allowed to proceed by a Pennsylvania federal court in 2015. It was a telling coda to the era.

The Decline and What Remained

By the mid-2010s, the toning shoe craze had effectively collapsed under the weight of its own implausibility. Retailers slashed prices to shift unsold inventory. Major brands quietly discontinued their lines. Avia pivoted back to traditional athletic footwear, activewear, and — briefly — wearable technology. The Avi-Motion became a relic, found mostly on discount shelves and in the back of wardrobes.

Avia’s parent company Sequential Brands filed for Chapter 11 bankruptcy protection in August 2021, and the brand was subsequently acquired by Galaxy Universal in September of that year for approximately $330 million as part of a broader portfolio deal. Today Avia lives on primarily as a budget-friendly athletic shoe, notable for its viral Avia 5000 sneaker that found a second life on TikTok as an astonishingly affordable running shoe — a far cry from the days of ambitious fitness promises.

A Cautionary Tale

The story of Avia toning shoes is ultimately a story about the collision between consumer desire and scientific reality. The desire was entirely human: people wanted to believe that a comfortable shortcut existed, that a shoe could do what discipline and effort are actually required to achieve. The industry — Avia very much included — was happy to supply that belief, dressed up in the language of biomechanics and supported by the veneer of clinical-sounding claims.

What brought the whole edifice down was not moral outrage, but evidence. Independent science, regulatory action, and ultimately the courts did what marketing could not undo: they forced the question of whether the products actually worked as advertised. They didn’t.

For consumers, the episode is a reminder to approach extraordinary health claims with proportional scepticism. For the footwear industry, it stands as a landmark lesson in the limits of selling hope without substance. And for Avia — a brand with genuine technical heritage and real innovation in its history — the toning shoe chapter represents a detour into wishful thinking that cost both money and credibility. The shoes are gone. The lesson, hopefully, is not.

Knee osteoarthritis (OA) is one of the most prevalent musculoskeletal
conditions worldwide, affecting hundreds of millions of people and
representing a leading cause of chronic pain and physical disability. As
populations age and rates of obesity rise, the burden of knee OA continues to
grow, placing enormous pressure on healthcare systems and diminishing
quality of life for countless individuals. Conventional treatments — ranging
from analgesics and physiotherapy to corticosteroid injections and, ultimately,
total knee replacement surgery — each carry limitations in efficacy,
tolerability, or cost. Against this backdrop, APOS therapy has emerged as an
innovative, non-invasive biomechanical approach that aims to address the
root mechanical causes of knee OA pain rather than merely managing its
symptoms.

What Is APOS Therapy?
APOS (All Phases of Stride) therapy is a personalised biomechanical
rehabilitation system developed in Israel in the early 2000s. At its core, the
system consists of specially designed convex-soled shoes, each fitted with two
independently adjustable pods positioned beneath the heel and forefoot.
These pods create a controlled degree of instability during walking,
challenging the neuromuscular system to continuously adapt and rebalance.
Unlike conventional orthotics, which provide rigid mechanical correction, the
APOS platform engages active muscle recruitment throughout every phase of
the gait cycle — hence the name.
The device is configured by a trained clinician following a detailed
biomechanical assessment. Using force-plate gait analysis, the clinician
identifies abnormal loading patterns, joint malalignment, and muscle
compensation strategies unique to each patient. The pods are then calibrated

in position to offload the most affected compartment of the knee joint —
typically the medial compartment, which bears the brunt of load in
varus-aligned knees — while simultaneously stimulating improved
neuromuscular control. Patients are instructed to wear the shoes for a
prescribed period each day, typically starting at around 30 minutes and
gradually increasing as tolerated.

The Biomechanical Rationale
The pathomechanics of knee osteoarthritis are well-established. In the
majority of patients, the medial compartment of the knee is subjected to
disproportionate loading, a phenomenon quantified by the knee adduction
moment (KAM) during gait. Elevated KAM is strongly associated with medial
cartilage degradation and disease progression. Traditional lateral wedge
insoles attempt to reduce KAM by shifting the ground reaction force laterally,
but clinical evidence for their long-term effectiveness has been inconsistent.
APOS therapy targets the KAM and broader gait dysfunction through a
dual mechanism. First, the precise positioning of the pods acts similarly to a
wedge insole in redistributing joint loads. Second — and more distinctively —
the instability introduced by the convex pods prompts continuous
proprioceptive feedback, training the periarticular muscles to better stabilise
the knee throughout the gait cycle. This neuromuscular re-education may
yield benefits that persist beyond the period of device use, potentially
modifying gait patterns in a durable way. There is also evidence that the
perturbation-based loading produced by the APOS platform can stimulate
cartilage metabolism, though this remains an area of ongoing investigation.

Clinical Evidence
A growing body of clinical research supports the effectiveness of APOS
therapy for knee OA. Several randomised controlled trials (RCTs) and
prospective cohort studies have demonstrated meaningful improvements in
pain, function, and quality of life. A landmark study published in the journal
Arthritis Care and Research found that patients undergoing APOS therapy
experienced significant reductions in pain intensity and improvements in self-reported physical function compared to control groups. Gait analysis data
corroborated these subjective outcomes, showing measurable reductions in
KAM and improvements in walking speed and step symmetry.
Longer-term follow-up studies have suggested that the benefits of APOS
therapy are maintained well after active treatment has concluded, lending
credence to the hypothesis that the intervention produces lasting
neuromuscular adaptations rather than simply offloading the joint during
device use. Some research has also indicated that APOS therapy can delay or
reduce the need for surgical intervention in patients who might otherwise be
considered candidates for knee replacement. This finding has significant
implications for healthcare resource utilisation, particularly given the costs,
risks, and extended rehabilitation associated with arthroplasty.

Advantages Over Conventional Approaches
APOS therapy offers several practical advantages that distinguish it from
other conservative treatments. Because it is integrated into a walking shoe
worn during routine daily activity, the therapy requires no dedicated exercise
sessions, gym attendance, or significant time commitment beyond the
prescribed wearing period. This is a meaningful advantage for older adults or
those with comorbidities that limit participation in structured exercise
programmes. The non-pharmacological nature of the therapy also means it is
free of the gastrointestinal, renal, and cardiovascular risks associated with
long-term non-steroidal anti-inflammatory drug (NSAID) use — a major
concern in the OA population, which skews elderly.
Furthermore, the individualised calibration of the APOS device ensures
that treatment is tailored to each patient’s specific biomechanical profile,
rather than applying a one-size-fits-all solution. This personalisation is
particularly valuable in a condition as biomechanically heterogeneous as knee
OA, where patient phenotypes vary considerably in alignment, muscle
strength, gait pattern, and disease severity.

Limitations and Considerations

Despite its promise, APOS therapy is not without limitations. The upfront
cost of the device and associated clinical assessments can be a barrier for some
patients, and reimbursement by insurers and public health systems varies by
jurisdiction. The therapy requires access to a trained APOS clinician and
specialised gait analysis equipment, which may limit availability in rural or
under-resourced settings. Some patients may also find the instability of the
convex pods challenging initially, particularly those with significant balance
impairment or peripheral neuropathy, although protocols are designed to
introduce perturbation gradually.
Critics have also noted that while the existing body of evidence is
encouraging, many studies have been conducted by groups with ties to the
APOS system’s developer, raising questions about potential bias. Independent,
large-scale RCTs with robust blinding and long follow-up periods are needed
to definitively establish the therapy’s place in the OA treatment hierarchy.
Head-to-head comparisons with other active interventions, such as structured
physiotherapy or lateral wedge insoles, would also be valuable.


Knee osteoarthritis remains a formidable challenge in musculoskeletal
medicine, and the search for effective, safe, and accessible treatments
continues. APOS therapy represents a genuinely novel contribution to this
landscape: a personalised, biomechanically-grounded intervention that
addresses the mechanical underpinnings of the disease rather than simply
dampening its symptomatic expression. The available clinical evidence is
promising, suggesting meaningful and durable reductions in pain and
improvements in physical function, alongside the potential to delay surgical
intervention. As independent research matures and access to the technology
broadens, APOS therapy may well secure a firm and important role in the
multidisciplinary management of knee osteoarthritis — offering patients a
path toward greater mobility and independence without the risks of surgery or
long-term medication use.

Not since the invention of the rubber outsole has the humble running shoe
undergone such a radical transformation. In the span of just a few years, footwear
engineers have rewritten the rulebook on what is biomechanically possible, lifting
world records off the track and delivering elite-level performance to everyday
runners worldwide. As we move through 2025 and into 2026, the pace of
innovation shows no sign of slowing. From laboratory-born foams that defy
conventional material science to geometry so aggressive it has regulators
scrambling, running shoes have become as much a feat of engineering as of
craftsmanship.

The Super-Foam Revolution
At the heart of every modern performance shoe is its midsole foam, and the
single biggest leap in recent years has been the shift away from traditional EVA
(ethylene-vinyl acetate) compounds toward two next-generation materials: PEBA
(polyether block amide) and ATPU (advanced thermoplastic polyurethane). EVA,
the workhorse of the industry for decades, compresses and loses energy with
every stride. PEBA and ATPU change the equation entirely.
PEBA-based foams — marketed under names such as Nike ZoomX, Adidas
Lightstrike Pro, and Saucony PWRRUN PB — are exceptionally light and springy,
returning a remarkable percentage of impact energy back to the runner with each
footfall. Think of them less like cushioning and more like a trampoline underfoot.
ATPU, the newer challenger, offers equally aggressive energy return with superior
durability. The ASICS Megablast and Puma Fast-R Nitro Elite 3 both deploy
ATPU to stunning effect in 2025, and the compound is rapidly scaling across
brand lineups heading into 2026. What was once reserved for $300 race-day
weapons is now trickling into everyday trainers — a genuine democratisation of elite performance.

Supercritical Foaming and the Science of Lightness

Alongside the chemistry of the foam itself, manufacturers have refined the
manufacturing process with a technique called supercritical foaming — injecting
nitrogen or carbon dioxide gas into molten polymer under extreme pressure
before allowing it to expand in a mould. The result is a cellular structure that is
simultaneously lighter, more resilient, and longer-lasting than conventionally
moulded foam. New Balance’s forthcoming 1080v15, due in early 2026, debuts an
entirely new compound called Infinion produced via this process, pushing the
heel stack to a near-maximum 40 mm while keeping the overall shoe weight
surprisingly low. Brooks has also adopted nitrogen-infused DNA Loft v3 foam in
its Adrenaline GTS 25, proving that even stability shoes aimed at overpronators
need not sacrifice liveliness for support.

Carbon Fibre Plates and the Propulsion Geometry
The carbon-fibre plate, first popularised by Nike’s Vaporfly series in 2017, has
become almost ubiquitous in high-end race footwear. Embedded in the midsole, a
curved carbon plate acts as a stiff lever that stores energy during the loading phase
and releases it explosively at toe-off, effectively adding mechanical propulsion to
a runner’s natural stride. Subsequent iterations have refined both the geometry
and composition of these plates: Adidas introduced its dual EnergyRods system,
arranging carbon rods in a biomechanically optimised arc, while Saucony and
ASICS have experimented with nylon-fibre composites to tune stiffness for
different distances. Nike’s Alphafly 4, arriving in early 2026, pairs its carbon plate
with a reworked Air unit for an even more propulsive toe-off, promising to
reclaim its standing as the marathon shoe of choice.
Research consistently demonstrates that well-designed plated shoes can
improve running economy — the energy cost of sustaining a given pace — by
roughly 2 to 4 percent compared with conventional trainers. Over a full
marathon, that efficiency gain translates directly into minutes off finishing times,
a margin large enough to be the difference between a personal best and a podium
position.

The Rise of Super Trainers
Perhaps the most significant cultural shift in running footwear is the blurring
of the line between daily trainer and race day rocket. Until recently, runners
maintained a strict two-shoe rotation: a heavy, durable workhorse for everyday
miles and a fragile, expensive carbon-plated racer reserved for competition.

Brands are now dismantling that divide with a new category: the super trainer.
These shoes strip out the rigid carbon plate — and its associated harshness — while
retaining the premium foam compound. The Adidas Adizero Evo SL exemplifies
the formula, placing Lightstrike Pro foam in a daily-wear chassis with a 39 mm
heel stack and a gentle 6 mm drop. The shoe delivers the trampoline-like energy
return of a race shoe without punishing the calves on a Tuesday morning
recovery run.

Stack Heights, Drop, and the Regulatory Debate
World Athletics limits competition shoes to a maximum 40 mm stack height
and one rigid plate — rules designed to preserve a degree of natural athletic
competition. Yet for the millions of recreational runners who will never toe an
elite start line, those regulations are irrelevant, and some brands have begun to
exploit that freedom with spectacular abandon. Puma’s aptly named Fast-RB
Nitro Elite pushes its heel stack to an extraordinary 58 mm, packing three carbon
plates into a structure designed to protect the legs of a marathon “tourist” rather
than win a championship. The shoe is technically banned from elite competition,
but for the amateur chasing a finish line rather than a podium, it represents the
outer edge of what cushioning technology can currently achieve.
Drop — the difference in stack height between heel and forefoot — has also
become a battleground. Traditional shoes sit at 8 to 10 mm, suiting heel strikers.
Under Armour’s Velociti Elite 3 challenges this orthodoxy with a radical 2 mm
drop, targeting biomechanically efficient midfoot strikers and signalling a broader
industry willingness to cater to a wider range of running gaits rather than
defaulting to a single standard geometry.

Upper Technology and Sustainability
Midsole innovation tends to steal the headlines, but upper construction has
evolved in parallel. Engineered knit uppers — using single-piece woven fabrics
that vary in density across zones of the foot — provide a sock-like fit that reduces
hotspots and slippage. Adidas’s woven Evo SL variant replaces the standard mesh
with an interlocked textile that offers improved breathability and a more
locked-in midfoot feel without added weight. Meanwhile, the industry is under
growing pressure to address its environmental footprint: brands including
Salomon and Brooks are incorporating recycled fibres and bio-based plastics into
uppers and outsoles, attempting to reconcile high performance with reducedenvironmental impact.

Looking Ahead
The trajectory of running shoe technology points toward an era in which elite
performance is no longer the exclusive preserve of professional athletes.
Supercritical foams, intelligently curved plates, and biomechanically tuned
geometry are converging into shoes that make every runner measurably faster,
more efficient, and better protected against fatigue. The challenge for brands and
regulators alike will be to manage a landscape in which the shoe itself is becoming
as significant a performance variable as training and talent. For the rest of us, the
golden age of running footwear is already here — and it fits in a shoebox.
Essay prepared May 2026. Sources: Sundried, Supwell, Runner’s World, and industry release data.

The Achilles tendon is the largest and strongest tendon in the human body,
connecting the gastrocnemius and soleus muscles of the calf to the calcaneus, or heel bone. Despite its remarkable tensile strength, it is also one of the most
commonly ruptured tendons in the body. Rupture typically occurs in physically
active individuals, particularly men between the ages of 30 and 50 who engage in recreational sports. The incidence of Achilles tendon rupture has risen
significantly over recent decades, mirroring increases in participation in sports
such as basketball, tennis, and distance running. The injury most often results
from sudden eccentric loading of the tendon, such as a forceful push-off or
unexpected dorsiflexion of the ankle. Effective treatment is essential to restore
function, prevent re-rupture, and enable patients to return to their pre-injury
activity level.

Diagnosis
Diagnosis of an Achilles tendon rupture is predominantly clinical. Patients
commonly describe a sudden, sharp pain in the back of the ankle, often likened
to being struck or kicked, even when no contact has occurred. Physical
examination typically reveals a palpable gap in the tendon, localised swelling,
bruising, and weakness in plantar flexion. The Thompson test, in which
squeezing the calf of a prone patient normally produces plantar flexion of the
foot, is a reliable diagnostic tool; absence of this response suggests a complete
rupture. Imaging is not always required for diagnosis but is frequently used to
confirm the extent of injury and guide management. Ultrasound is the first-line
imaging modality due to its accessibility, low cost, and dynamic capabilities.
Magnetic resonance imaging (MRI) provides greater anatomical detail and is
reserved for equivocal cases or pre-surgical planning.

Non-Operative Management
Historically, operative treatment was favoured due to concerns about higher
re-rupture rates with conservative management. However, contemporary
evidence has significantly challenged this view. Non-operative treatment
involves immobilisation of the ankle, typically in an equinus position (plantar
flexion), using a cast or functional brace, followed by a carefully structured
rehabilitation program. Early functional rehabilitation protocols, which allow
controlled weight-bearing and progressive range-of-motion exercises, have
demonstrated outcomes comparable to surgical repair in terms of re-rupture
rate and functional recovery. A landmark randomised controlled trial by Willits
et al. (2010) found no significant difference in re-rupture rates between operative
and non-operative groups when both received an accelerated rehabilitation
protocol. Non-operative management avoids surgical risks including wound
infection, nerve damage, and deep vein thrombosis, making it an increasingly
preferred option for lower-demand patients, the elderly, and those with
comorbidities that increase operative risk.

Operative Management
Surgical repair of the Achilles tendon involves suturing the torn ends of the
tendon together, restoring its continuity and tension. Open repair, the traditional
approach, provides direct visualisation of the tendon and is associated with low
re-rupture rates, typically cited at less than 3 to 5 percent. The procedure is
performed under general or regional anaesthesia, with the patient placed prone.
The torn tendon ends are identified, debrided, and repaired using strong
absorbable or non-absorbable sutures in a variety of configurations, the most
widely used being the Kessler and Krackow techniques. Percutaneous and
minimally invasive repair techniques have been developed to reduce the wound
complication rates associated with open surgery, which can be as high as 20
percent in some series. These techniques use small stab incisions and specialised
devices to pass sutures through the tendon with minimal soft tissue disruption.
Studies have shown minimally invasive approaches achieve equivalent strength
and functional outcomes to open repair while reducing complications, though
they carry a higher risk of sural nerve injury if not performed with meticulous
technique.

Rehabilitation
Regardless of whether management is operative or non-operative,
rehabilitation is a critical determinant of outcome. Modern rehabilitation
protocols emphasise early controlled mobilisation rather than prolonged
immobilisation. Weight-bearing in a functional boot with heel raises typically
commences within one to two weeks of injury or surgery. Progressive
range-of-motion exercises, strengthening of the calf complex, proprioceptive
training, and gradual reintroduction of sport-specific activities follow a
structured timeline over several months. Full return to sport is generally not
expected before nine to twelve months, and some studies report that peak
strength recovery may take up to two years. Physical therapy plays a pivotal role throughout recovery, with eccentric calf strengthening and plyometric loading forming the cornerstone of sport-specific rehabilitation. Patient compliance with rehabilitation protocols is strongly associated with favourable outcomes.

Complications and Prognosis
Both treatment pathways carry risks. Surgical complications include wound
dehiscence, infection, sural nerve injury, deep vein thrombosis, and pulmonary
embolism. Non-operative management carries a historically higher re-rupture
rate, though this gap has narrowed considerably with functional rehabilitation
protocols, with pooled re-rupture rates now reported in the range of 2 to 5
percent for both approaches. Long-term prognosis following Achilles tendon
rupture is generally favourable, with the majority of patients returning to
pre-injury activity levels. However, residual deficits in plantarflexion strength,
endurance, and power are common, and some patients report persistent
symptoms for years after injury. Psychological factors, including fear of
re-injury and reduced confidence in the limb, can also impede full functional
recovery.

Conclusion
The management of Achilles tendon ruptures has evolved considerably over
the past two decades. The traditional assumption that surgery is always superior
has been replaced by a more nuanced, evidence-based approach that recognises
non-operative functional rehabilitation as a viable and often equivalent
alternative for many patients. Treatment decisions should be individualised,
taking into account patient age, activity level, occupational demands, comorbidities, and patient preference. Operative repair may still be preferred in
young, high-demand athletes seeking to minimise re-rupture risk and optimise
the speed of return to sport. Regardless of the chosen approach, a structured and
progressive rehabilitation program is indispensable to achieving the best possible
functional outcome. Ongoing research into augmentation techniques, biologics,
and optimised rehabilitation protocols continues to refine and improve the
management of this challenging injury.

The human foot is a marvel of biomechanical engineering, composed of
twenty-six bones, thirty-three joints, and more than a hundred muscles, tendons,
and ligaments working in concert to support the body’s weight and propel it
forward. Yet within this precisely orchestrated architecture, anatomical
variations are surprisingly common. One of the most frequently encountered is
the accessory navicular, an extra ossicle (small bone) located on the medial aspect
of the foot near the navicular bone. Estimated to occur in approximately ten to
fourteen percent of the general population, it is most often an incidental finding
– a harmless quirk of development. In a smaller subset of individuals, however, it
becomes a significant source of medial foot pain, altered gait, and functional
disability. Understanding the anatomy, classification, biomechanical
implications, and treatment options of the accessory navicular is essential for any
clinician working with foot and ankle conditions.

Anatomy and Embryology
The navicular is a tarsal bone situated on the medial column of the foot,
articulating with the talus proximally and the three cuneiform bones distally. It
serves as the keystone of the medial longitudinal arch and is the primary
attachment site for the tibialis posterior tendon, one of the most important
dynamic stabilisers of that arch. The accessory navicular arises from a secondary
ossification centre that fails to fuse with the main navicular during skeletal
development. In most people, this centre either never appears or fuses
seamlessly during adolescence. In those who retain it, the result is a distinct bony
prominence on the medial and plantar aspect of the navicular.
Three subtypes have been described in the literature, most commonly
attributed to Geist (1914) and later refined by others. Type I, also called an os
tibiale externum, is a small sesamoid bone embedded entirely within the tibialis
posterior tendon and is generally asymptomatic. Type II is the most clinically

relevant: a larger ossicle connected to the navicular by a fibrocartilaginous
synchondrosis. Because the tibialis posterior tendon inserts partly onto this
accessory bone, mechanical forces across the junction can produce microtrauma,
inflammation, and pain. Type III represents a fused or partially fused accessory
navicular, creating a prominent ‘cornuate’ navicular with an enlarged medial
tuberosity. Although structurally fused, this type can still produce symptoms due
to its bony prominence and its effect on tendon mechanics.

Clinical Presentation
Accessory navicular syndrome – the symptomatic form of the condition –
most commonly presents in adolescence, coinciding with a period of rapid
growth and increased physical activity. It is somewhat more prevalent in females
than males, and a bilateral presentation is found in up to fifty percent of cases.
The hallmark symptom is medial foot pain, typically localised to the bony
prominence on the inner border of the midfoot. The area is often tender to
direct palpation, and the prominence itself may be visibly or palpably enlarged,
causing irritation from footwear. Activity-related pain – particularly running,
jumping, or prolonged standing – is a consistent complaint.
A key associated finding is pes planus, or flatfoot deformity. Because the
accessory navicular disrupts the normal insertion mechanics of the tibialis
posterior tendon, the dynamic support of the medial longitudinal arch is
compromised. Patients may consequently develop or worsen a pre-existing
flatfoot, contributing to broader biomechanical consequences such as hindfoot
valgus, forefoot abduction, and altered lower limb alignment. These secondary
changes can themselves become sources of pain and dysfunction if left
unaddressed.

Diagnosis
Diagnosis is primarily clinical but is confirmed radiographically.
Weight-bearing plain radiographs of the foot, including anteroposterior, lateral,
and oblique views, will typically demonstrate the accessory ossicle. The oblique
view is particularly valuable for visualising the synchondrosis in Type II cases.
Where plain films are inconclusive or when the extent of soft tissue involvement
needs assessment, magnetic resonance imaging (MRI) is the modality of choice.

MRI can identify bone marrow oedema at the synchondrosis – a reliable
indicator of active inflammation and the likely source of pain. Technetium bone
scanning has also been used to demonstrate increased uptake at the accessory
navicular site, confirming its symptomatic status.
Conservative Management
The vast majority of patients with symptomatic accessory navicular respond
well to non-operative treatment, and conservative management should always be
the first line of care. Rest from aggravating activities, non-steroidal
anti-inflammatory medications, and ice application form the cornerstone of
initial management. Immobilisation in a below-knee cast or a removable walking
boot for four to six weeks is highly effective in acute or severe flares, allowing the
inflamed synchondrosis to settle.
Once the acute phase has resolved, custom orthotic devices are the most
important tool for long-term symptom control. A well-fitted medial arch
support offloads the navicular prominence, reduces stress at the synchondrosis,
and helps correct the biomechanical consequences of the associated flatfoot
deformity. Footwear modification – favouring supportive, wide-toed shoes that
avoid direct pressure over the prominence – is equally important. Physiotherapy
targeting tibialis posterior strengthening, calf flexibility, and intrinsic foot muscle
activation is valuable in rebuilding dynamic arch support. Corticosteroid
injection into the synchondrosis can provide medium-term relief in refractory
cases, though its use is generally reserved for adults given the potential effects on
developing tissue in younger patients.

Surgical Management
When conservative measures fail after a sustained trial of at least three to six
months, surgical intervention is considered. The most widely performed
procedure is the Kidner operation, first described in 1929, which involves
excision of the accessory navicular and re-routing of the tibialis posterior tendon
to a more plantar and distal position on the native navicular. This re-attachment
is intended to improve the tendon’s mechanical advantage in supporting the
medial arch. Long-term outcomes following the Kidner procedure are generally
favourable, with the majority of patients reporting significant pain relief and

return to normal activities.
More recently, some surgeons have advocated for simple excision of the
ossicle without tendon re-routing, particularly in Type I cases or where the
tendon insertion is largely intact on the native navicular. Arthroscopic or
minimally invasive techniques for accessory navicular excision have also been
described, offering the potential advantages of smaller incisions, reduced soft
tissue disruption, and faster recovery. In cases with significant associated flatfoot
deformity, additional procedures to reconstruct the medial arch – such as
calcaneal osteotomy or medial column stabilisation – may be undertaken
concurrently.

The accessory navicular is a common anatomical variant that, in a
meaningful minority of individuals, evolves into a painful and functionally
limiting condition. Its close relationship with the tibialis posterior tendon and the
medial longitudinal arch means that its consequences can extend well beyond
simple bony prominences. A thorough understanding of its subtypes, clinical
presentation, and pathomechanics enables accurate diagnosis and the selection
of appropriate management strategies. With a well-structured conservative
programme, most patients achieve satisfactory outcomes without the need for
surgery. For those who do require operative intervention, modern techniques
offer reliable and durable relief. The accessory navicular is a reminder that even
the smallest structural variations in the foot can have outsized functional
consequences – and that attentive, individualised care makes all the difference.

On the warm evening of 10 September 1960, a slender Ethiopian soldier
jogged to the start line of the Olympic marathon in Rome. He wore no
shoes. While the rest of the field arrived in purpose-built racing flats, Abebe
Bikila planted his bare feet on the cobblestones of the Appian Way and,
within two hours and fifteen minutes, rewrote the history of distance
running. It was not merely a sporting triumph; it was a declaration of
African capability broadcast to a world that had long underestimated the
continent.

Abebe Bikila was born on 7 August 1932 in the small village of Jato, in
the mountains of central Ethiopia. He grew up as a shepherd boy,
accustomed to moving across vast, rocky highland terrain, often with little
or nothing on his feet. At the age of twenty-four he joined the Imperial
Bodyguard of Emperor Haile Selassie, where he was noticed for his
prodigious physical fitness and exceptional lung capacity. His formal
running career began almost by accident. A friend invited him to watch a
training session run by the Finnish coach Onni Niskanen, who had been
sent to Ethiopia to develop the country’s athletics programme. Niskanen
recognised the young guard’s potential immediately and began coaching
him in earnest. Bikila trained at altitudes above 2,000 metres, a natural
physiological advantage that would prove decisive in competition.
When Ethiopia’s Olympic selection committee chose Bikila for Rome
in 1960, he was virtually unknown outside his own country. He had never
run an international marathon. The decision to race barefoot was partly
practical and partly symbolic. Adidas, the official supplier, had run out of
shoes that fitted him properly. Bikila had trained barefoot throughout his
preparation and felt more comfortable without shoes on the hard surface.
Niskanen agreed. In hindsight, the decision was inspired.

The Rome marathon was run at night under flickering torchlight, a
deliberate homage to the classical world, with the course winding along the
ancient Appian Way and finishing at the Arch of Constantine. The
atmosphere was theatrical and haunting. Bikila bided his time in the early
stages, settling into a compact, metronomic stride that consumed the road
with quiet efficiency. By the halfway point he had moved into contention.
By the 30-kilometre mark he was at the front. Moroccan runner Rhadi Ben
Abdesselam, the pre-race favourite, tried to match him but could not. Bikila
crossed the finish line in 2 hours, 15 minutes and 16 seconds, breaking the
world record by nearly eight minutes. He was so composed upon finishing
that he immediately began stretching and performing calisthenics, as if the
race had barely taxed him.

The symbolism of the victory was enormous and was not lost on the
watching world. Ethiopia was one of only two African nations never
colonised by a European power, the other being Liberia. It had successfully
repelled an Italian invasion in 1896 at the Battle of Adwa, only to suffer
Mussolini’s brutal occupation from 1936 to 1941. That Bikila won on Italian
soil, and won in Rome itself, carrying the Ethiopian flag with his bare feet,
was a profound act of postcolonial pride. Whether or not he consciously
framed it in those terms, millions of Africans and people of African descent
did. He was the first Black African to win an Olympic gold medal, and he
had done it in the most emphatic manner imaginable.

Four years later, at the 1964 Tokyo Olympics, Bikila proved that Rome
had been no fluke. This time he wore shoes. He had undergone an
appendectomy just forty days before the race, and his doctors had advised
him not to compete. He ignored them. He won again, setting another world
record with a time of 2 hours, 12 minutes and 11 seconds, becoming the first
person in history to win consecutive Olympic marathon gold medals. Once
more he finished the race in a condition that left his rivals bewildered. He
told reporters he could have run another ten kilometres. Whether or not
that was bravado, no one had the legs to test it.
His story, however, took a devastating turn. In March 1969, Bikila was
involved in a car accident near Addis Ababa that left him paralysed from the waist down. The nation was grief-stricken. Yet Bikila, with characteristic
resilience, refused to accept defeat. He took up competitive archery and
handpulled sledging, competing in the 1970 Stoke Mandeville Games for
Paralympic athletes. He died on 25 October 1973 from a brain
haemorrhage, complications arising from his injury. He was forty-one
years old. Ethiopia declared a national day of mourning. Emperor Haile
Selassie attended the state funeral in person.

The legacy of Abebe Bikila extends far beyond athletics. He opened a
door that Ethiopian and Kenyan runners would sprint through in the
following decades, establishing East Africa as the dominant force in
long-distance running. Names like Mamo Wolde, Miruts Yifter, Haile
Gebrselassie, Kenenisa Bekele, and Eliud Kipchoge all run in his shadow. He
also helped shift the global perception of African athletes from exotic
curiosities to serious competitors worthy of respect and study. In the years
since his death, sports scientists have revisited his barefoot running style
with fresh eyes, noting that his natural gait anticipated many of the
biomechanical insights that would only gain mainstream attention half a
century later.

Statues and portraits of Bikila stand in Addis Ababa. His image appears
on Ethiopian stamps and currency. A stadium bears his name. Yet perhaps
the most enduring monument to the man is the simple image that the
world cannot forget: a slight figure running in darkness on ancient stones,
barefoot and unhurried, moving through history as if it were merely
another training run through the highlands he called home.